Core Viewpoint - The article discusses the investment position of the analyst in HROW, indicating a beneficial long position through various means such as stock ownership and derivatives [1]. Group 1 - The analyst expresses personal opinions regarding HROW and clarifies that they are not receiving compensation for the article, except from Seeking Alpha [1]. - There is an emphasis on the importance of individual due diligence for readers before making investment decisions, highlighting that the commentary is not personalized investment advice [2]. - The article notes that past performance is not indicative of future results, and any views expressed may not reflect the opinions of Seeking Alpha as a whole [3].

Group 1 - Harrow (HROW) shares have increased by 10.7% in the past four weeks, closing at $40.01, with a mean price target of $61.31 indicating a potential upside of 53.2% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $8.32, where the lowest estimate is $52.20 (30.5% increase) and the highest is $76.00 (90% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 39% over the past month [11][12] Group 2 - HROW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] - While price targets can be misleading, the direction implied by them may serve as a useful guide for potential price movements [10][14]

Core Insights - The industrial hemp stocks are experiencing significant activity, with Tilray rising over 9%, Harrow and Veru increasing by more than 6%, and Aurora Cannabis up nearly 2% [1] - A report from the Washington Post indicates that Trump expressed intentions to classify cannabis as a lower-risk substance during a fundraising dinner in New Jersey, which could simplify the cannabis trade and enhance profitability in this multi-billion dollar industry [1] - Trump is expected to make decisions regarding cannabis in the coming weeks, which could have substantial implications for the market [1] Company Performance - Tilray's stock increased by over 9% [1] - Harrow and Veru both saw stock increases of more than 6% [1] - Aurora Cannabis experienced a rise of nearly 2% [1] - Other companies like Canopy Growth and Teva Pharmaceuticals also saw stock increases of over 1.5% [1]

Company Overview - Harrow (HROW) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.00 per share, indicating a +100% change [1][3] - Revenues are projected to be $65.32 million, reflecting a 33.5% increase from the same quarter last year [3] Earnings Expectations - The upcoming earnings report is anticipated to be released on August 11, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised down by 7.89% over the last 30 days, indicating a bearish sentiment among analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Harrow is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1,000.01%, which complicates predictions of an earnings beat [12] - Harrow currently holds a Zacks Rank of 3, suggesting a neutral outlook [12] Historical Performance - In the last reported quarter, Harrow was expected to post earnings of $0.02 per share but instead reported a loss of -$0.38, resulting in a surprise of -2,000.00% [13] - Over the past four quarters, Harrow has beaten consensus EPS estimates two times [14] Industry Context - Aclaris Therapeutics (ACRS), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.13 per share for the same quarter, indicating a year-over-year change of +13.3% [18] - Aclaris's revenues are expected to be $1.55 million, down 44% from the previous year, with a consensus EPS estimate revised 1.4% higher recently [19]

Core Viewpoint - Harrow (HROW) reported a quarterly loss of $0.38 per share, significantly missing the Zacks Consensus Estimate of $0.02, representing an earnings surprise of -2,000% [1] - The company's revenues for the quarter were $47.83 million, falling short of the Zacks Consensus Estimate by 19.88%, but showing an increase from $34.59 million year-over-year [2] Financial Performance - Harrow's loss per share increased from $0.28 a year ago to $0.38 this quarter, indicating a decline in financial performance [1] - The company has surpassed consensus EPS estimates two times over the last four quarters, but missed revenue estimates in the latest quarter [2] Stock Performance - Harrow shares have declined approximately 26.7% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current Zacks Rank for Harrow is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $68.63 million, and for the current fiscal year, it is $0.47 on revenues of $286.4 million [7] - The trend of estimate revisions for Harrow is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Harrow belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. The predictions and opinions presented are based on the author's analysis and reflect a probabilistic approach, not absolute certainty. Efforts have been made to ensure the information's accuracy, but inadvertent errors may occur. Readers are advised to in ...